Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco

Diagnostic Pathology

Afaf Amarti¹  Omar Mesbahi²  Abdelaziz Bannani³  My Abdelilah Melhouf¹  Kaoutar Moumna¹  Sofia Jayi³  Sanae Chahbouni¹  Hinde El Fatemi¹ 

[1] Department of Pathology, Hassan II teaching hospital, Fez, Morocco;Department of Oncology, Hassan II teaching hospital, Fez, Morocco;Department of Gynecology, Hassan II teaching hospital, Fez, Morocco

关键词: Immunohistochemistry;    Antibodies;    Staging;    Luminal B subtype;    Molecular classification;    Breast cancer;   

Others  :  807792
DOI  :  10.1186/1746-1596-7-170

 received in 2012-10-15, accepted in 2012-12-04,  发布年份 2012

【 摘 要 】

Background

Breast cancer may be classified into luminal A, luminal B, HER2+/ER-, basal-like and normal-like subtypes based on gene expression profiling or immunohistochemical (IHC) characteristics. The aim of our study is to show the molecular profile characteristic of breast cancer in the North African population of Morocco. This work showed preliminary results and correlations with clinicopathological and histological parameters. Three hundred and ninety primary breast carcinomas tumor tissues were immunostained for ER, PR, HER2, CK5/6, CK8/18 and Ki67 using paraffin tissue.

Methods

We reviewed 390 cases of breast cancer diagnosed on January 2008 to December 2011 at the Department of pathology, Hassan II teaching hospital, Fez, Morocco. Age, size tumor, metastatic profile, node involvement profile, histological type and immunohistochemical profile were studied.

Results

The average age was 46 years; our patients were diagnosed late with a high average tumor size. Luminal B subtype was more prevalent (41.8%), followed by luminal A (30.5%), basal-like (13, 6%), Her2-overexpressing (9, 2%), and unclassified subtype (4.9%).

Conclusion

This study showed that molecular classification and biological profile may be different according to geographical distribution, to encourage further studies to know the genomic profile of tumors and the environment.

Virtual slide

http://www.diagnosticpathology.diagnomx.eu/vs/1675272504826544 webcite

【 授权许可】

   
2012 EL FATEMI; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
• [2]Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
• [3]Sorlie T: Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004, 40:2667-26675.
• [4]Aleix P, Parker JS, Olga K, Cheng F, Chad L, Herschkowitz JI, Xiaping H, Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68. BioMed Central Full Text
• [5]Bhargava R, Striebel J, Beriwal S, et al.: Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009, 2:444-455.
• [6]Tang P, Wang J, Bourne P: Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol 2008, 39:506-513.
• [7]Tavassoli F, Devilee P (Eds): Pathology and genetics of tumours of the breast and female genital organs, world health organization classification of tumours. Lyon: IARC Press; 2003.
• [8]Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991, 19(5):403-410.
• [9]American Joint Committee on Cancer: AJCC cancer staging handbook. 2010. http://www.springer.com/medicine/surgery/cancer+staging?SGWID=0-40654-0-0-0 webcite, Last accessed on 14/1/2011
• [10]Wolff AC, Elizabeth M, Hammond H, et al.: Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. American Society of Clinical Oncology/College of American Pathologists. J Clin Oncol 2007, 25:118-145.
• [11]Prat A, Ellis MJ, Perou CM: Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2011, 9(1):48-57.
• [12]Arvydas L, Aida L, Valerijus O, Darius D, Sonata J, Juozas L: Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol 2012, 7:27. BioMed Central Full Text
• [13]Ross JS, Fletcher JA, Bloom KJ, et al.: Targeted therapy in breast cancer. Mol Cell Proteomics 2004, 3:379-398.
• [14]Junichi K, Takoya M, Takanori I, et al.: The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races [abstract]. Breast 2007, 16(Suppl 2):S72-S77.
• [15]Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, et al.: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006, 94:1604-1609.
• [16]Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, et al.: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005, 23:5323-5333.
• [17]Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y: Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 2002, 8:3454-3460.
• [18]Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, Inazawa J, Tamaki K, Mochizuki H, Tamai S, Hiraide H: Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 2005, 96:48-53.
• [19]Walker RA, Dearing SJ: Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999, 53:167-176.
• [20]Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
• [21]Kristensen VN: Divide and conquer: the genetic basis of molecular sub classification of breast cancer. EMBO Mol Med 2011, 3:183-185.
• [22]Gomes DS, Débora B, Porto SS, Helenice G: Lobular neoplasia: frequency and association with other breast lesions. Diagn Pathol 2011, 6:74. 9 August 2011 BioMed Central Full Text
• [23]Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO: High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007, 31:417-426.
• [24]Bratthauer GL, Tavassoli FA: Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch 2002, 440:134-138.
• [25]Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, Moriarty RM, Wood WC, Lee HY, Yang L: Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol 2007, 71(1):101-111.
• [26]Bockbrader KM, Tan M, Sun Y: A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005, 24(49):7381-7388.
• [27]Yutao Z, Jianhua Z, Yun T, Feng L, Hongyuan Z, Bofang P, Chifeng Z, Rong F: X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol 2011, 6:49. BioMed Central Full Text
• [28]Matter K, Balda MS: Signaling to and from tight junctions. Nat Rev Mol Cell Biol 2003, 4:225-236.
• [29]Tsukita S, Furuse M: Occludin and claudins in tight-junction strands: leading or supporting players? Trends Cell Biol 1999, 9:268-273.
• [30]Tsukita S, Furuse M, Itoh M: Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001, 2:285-293.
• [31]Santos PB, Zanetti JS, Silva AR, Beltrão EIC: Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagnostic Pathology 2012, 7:104. BioMed Central Full Text
• [32]MariadelasMercedes N, Fernando P, Florencia P, Néstor L, Hugo K, Silvana N, Alejandro G, Alejandra A, Boris E, Valeria D, Miembro de la Carrera de Investigador del Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET): Immunohistochemical characterization of neoplastic cells of breast origin. Diagn Pathol 2012, 7:73. BioMed Central Full Text